UK approves GSK Covid drug, appears effective against Omicron

Agence France-Presse
UK approves GSK Covid drug, appears effective against Omicron
A video grab from footage broadcast by the UK Parliament's Parliamentary Recording Unit (PRU) shows Britain's Health Secretary Sajid Javid making a statement relating to the Omicron variant of coronavirus, in the House of Commons in London on November 29, 2021. All adults in Britain will now be able to get a third Covid jab, a government scientific advisory body said Monday, as concern mounted about the spread of the new Omicron variant. "We're advising that the booster programme should now be extended to adults aged 18 to 39 years old," said Wei Shen Lim, of the Joint Committee on Vaccination and Immunisation. PRU / AFP

LONDON, United Kingdom — British regulators on Thursday approved a GlaxoSmithKline drug to treat those at high risk of developing severe Covid-19 symptoms, with the manufacturer saying it appears effective against the new Omicron variant.

The antibody treatment, sotrovimab, "was found to be safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease," said the Medicines and Healthcare products Regulatory Agency (MHRA).

Preclinical data showed that the drug "retains activity against key mutations of the new Omicron SARS-CoV-2 variant," GlaxoSmithKline (GSK) said in a statement.

"To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO)," it added.

Testing is ongoing "to confirm the neutralizing activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021."

A single dose of the drug was found to reduce the risk of hospitalization and death by 79 percent in high-risk adults with symptomatic COVID-19 infection, according to the MHRA.

Sotrovimab was developed by Britain's GSK and Vir Biotechnology based out of California.

It is a monoclonal antibody, a type of protein that attaches to the spike protein of the coronavirus, reducing its ability to enter the body's cells.

  • Latest
  • Trending
Are you sure you want to log out?

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

or sign in with